Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Simple Summary Diverse evidence revealed that CD4+ T cells play an important role in
antitumor immunity by promoting or suppressing cytotoxic T cell responses. This review …

Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Whereas preclinical investigations and clinical studies have established that CD8+ T cells
can profoundly affect cancer progression, the underlying mechanisms are still elusive …

Cytotoxic T cells are important effectors of anti-tumor immunity. While tumor killing is
ascribed to CD8+ T cell function, pre-clinical and clinical studies have identified intra …

Simple Summary While most cancer immunotherapies have focused on CD8+ T cells as the
main drivers of antitumor immunity, increasing evidence indicates that CD4+ T cells also …

Over the past decades, tumor-resident immune cells have been extensively studied to
dissect their biological functions and clinical roles. Tumor-infiltrating CD8+ T cells, because …

Cancer immunotherapy focuses mainly on anti‐tumour activity of CD 8+ cytotoxic T
lymphocytes (CTL s). CTL s can directly kill all tumour cell types, provided they carry …

The importance of CD4 T cells in orchestrating the immune system and their role in inducing
effective T cell-mediated therapies for the treatment of patients with select established …